Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KHK | P50053 | 3/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865738 | 0.87 | KHK (0.41) | USP2POLBSMN1; SMN2KHKPDE5A | |
| SCHEMBL13865754 | 0.82 | KHK (0.40) | USP2POLBSMN1; SMN2KHKPDE5A | |
| SCHEMBL4521650 | 0.81 | KHK (0.45) | USP2POLBSMN1; SMN2LMNAKHK | |
| SCHEMBL13865810 | 0.80 | KHK (0.51) | POLBSMN1; SMN2LMNAL3MBTL1KHK | |
| SCHEMBL13865746 | 0.80 | PDE5A (0.39) | USP2POLBSMN1; SMN2KHKPDE5A | |
| SCHEMBL4516105 | 0.79 | RXFP1 (0.49) | USP2POLBSMN1; SMN2KHKPDE5A | |
| SCHEMBL4509689 | 0.79 | CYP1A2 (0.49) | USP2SMN1; SMN2KHKPDE5AHTT | |
| SCHEMBL13865758 | 0.78 | KHK (0.45) | USP2SMN1; SMN2LMNAKHKPDE5A | |
| SCHEMBL13865775 | 0.78 | KHK (0.42) | USP2POLBSMN1; SMN2LMNAKHK | |
| SCHEMBL4498040 | 0.77 | TSHR (0.41) | USP2SMN1; SMN2KHKPDE5ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | claimed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | claimed |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | USP2 1541/4885POLB 1938/4885SMN1; SMN2 980/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | USP2 1549/4885POLB 1160/4885SMN1; SMN2 714/4885 |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | USP2 970/4885POLB 701/4885SMN1; SMN2 3300/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | USP2 1541/4885POLB 1938/4885SMN1; SMN2 980/4885 |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | PDE5A, ECE1, PDE3A | USP2 1564/4885POLB 1542/4885SMN1; SMN2 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.